Previous 10 | Next 10 |
FLORHAM PARK, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Vers...
PDS Biotechnology (NASDAQ:PDSB) said that the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) accepted its clinical trial application (CTA) to start a study, called VERSATILE-002, of PDS0101 in combination with Merck's (MRK) Keytruda (pembrolizumab). The compa...
FLORHAM PARK, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s propri...
Phase 2 Triple Combination Study Data To Be Presented At ASCO. PDS Biotech will be making two data presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 3-7. A poster presentation of preliminary data from the Phase 2 Triple Combination trial is sc...
Phase 2 VERSATILE Study Data To Be Presented. PDS Biotech will be making two data presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 3-7. A poster presentation of preliminary data from the Phase 2 VERSATILE-002 clinical trial is scheduled for J...
Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or meta...
PDS Biotechnology (NASDAQ:PDSB) reported data from an ongoing phase 2 trial of PDS0101 in combination with M9241 and bintrafusp alfa in certain cancers. The triple combination is being evaluated in patients with advanced HPV-positive anal, cervical, head and neck, vaginal, and vulvar can...
Preliminary data from first 19 patients treated with PDS0101 in combination with KEYTRUDA ® (pembrolizumab) demonstrates 41% response rate thus far for first line recurrent or metastatic head and neck cancer, in comparison to the published results of approximately 19% for...
77% of checkpoint inhibitor (CPI) refractory patients alive at median follow up of 12 months 75% of CPI naïve patients alive at median follow up of 17 months Anti-tumor objective responses seen in 88% of CPI naïve patients and 63% CPI refractory patients (high do...
FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, today announced its management team will ho...
News, Short Squeeze, Breakout and More Instantly...
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NASDAQ Market:
PDS Biotechnology Corporation Website:
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectiou...
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 (GLOBE NEW...